SCHEMBL3940930

SCHEMBL3940930

CN(C)S(=O)(=O)NC=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5572071 0.77
SCHEMBL13773387 0.74 CA1 (0.33)
SCHEMBL8143416 0.70 LMNA (0.31)
SCHEMBL3759349 0.70 CA1 (0.46)
SCHEMBL7355622 0.69 ALDH1A1 (0.41)
SCHEMBL4177259 0.66 ALDH1A1 (0.54)
SCHEMBL41866 0.65
SCHEMBL54558 0.65
SCHEMBL22680593 0.64 CA1 (0.39)
SCHEMBL2232334 0.63

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3743411-B1 HERBICIDAL 3-PHENYLISOXAZOLIN-5-CARBOXAMIDES OF CYCLOPENTENYL CARBOXYLIC ACID DERIVATIVES BAYER AG (DE) 2022-12-21 EP disclosed
EP-3770148-A1 RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF Beijing Tide Pharmaceutical Co., Ltd. (CN) 2021-01-27 EP disclosed
EP-3760620-A1 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USAGE THEREOF Beijing Tide Pharmaceutical Co., Ltd. (CN) 2021-01-06 EP disclosed
WO-2019179515-A1 RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF 北京泰德制药股份有限公司 2019-09-26 WO disclosed
EP-2576586-B1 C-28 AMIDES OF MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2015-08-12 EP disclosed
EP-2305697-A2 Macrocyclic inhibitors of Hepatitis C virus replication Intermune, Inc. (US) 2011-04-06 EP disclosed
EP-2305698-A2 Macrocyclic inhibitors of Hepatitis C virus replication Intermune, Inc. (US) 2011-04-06 EP disclosed
US-20090207712-A1 OPTICAL RECORDING MEDIUM AND METHOD OF RECORDING VISIBLE INFORMATION FUJIFILM CORPORATION (JP) 2009-08-20 US disclosed
EP-2003644-A9 OPTICAL RECORDING MEDIUM AND VISIBLE INFORMATION RECORDING METHOD Fujifilm Corporation (JP) 2009-04-15 EP disclosed
US-20090058982-A1 OPTICAL RECORDING MEDIUM AND METHOD OF RECORDING VISIBLE INFORMATION FUJIFILM CORPORATION (JP) 2009-03-05 US disclosed
US-7485633-B2 RNA polymerase, HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase inhibitor; liver disease; (+/-)-8-Cyclohexyl-N-4-(morpholinosulfonyl)-1,1a,2,12b-tetrahydro-11-methoxy-1a-(3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)cycloprop[d]indolo[2,1-a][2]benzazepine-5-carboxamide BRISTOL-MYERS SQUIBB COMPANY (US) 2009-02-03 US disclosed
US-20090022047-A1 OPTICAL RECORDING MEDIUM AND METHOD OF RECORDING VISIBLE INFORMATION FUJIFILM CORPORATION (JP) 2009-01-22 US disclosed
EP-2003644-A2 OPTICAL RECORDING MEDIUM AND VISIBLE INFORMATION RECORDING METHOD Fujifilm Corporation (JP) 2008-12-17 EP disclosed
WO-2008112473-A1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2008-09-18 WO disclosed
WO-2007014925-A1 MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS TIBOTEC PHARMACEUTICALS LTD. (IE) 2007-02-08 WO disclosed